Antitumoral effect of Ocoxin in hepatocellular carcinoma
- Elena Díaz‑Rodríguez
- Al‑Mahy El‑Mallah
- Eduardo Sanz
- Atanasio Pandiella
Affiliations: Institute of Molecular and Cellular Cancer Biology, CSIC‑University of Salamanca, 37007 Salamanca, Spain, Catalysis, S.L., 28016 Madrid, Spain
- Published online on: June 21, 2017 https://doi.org/10.3892/ol.2017.6440
Copyright: © Díaz‑Rodríguez
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Hepatocellular carcinoma (HCC) is becoming one of the most prevalent types of cancer worldwide. The most efficient types of treatment at present include surgical resection and liver transplantation, but these treatments may only be used in a small percentage of patients. In order to identify novel therapeutic strategies for this disease, the present study explored the potential antitumoral effect of Ocoxin® oral solution (OOS) in HCC. OOS inhibited the proliferation of HCC cell lines in a time‑ and dose‑dependent manner, being more efficient when used in combination with sorafenib, a standard of care treatment for patients diagnosed with advanced‑stage disease. Mechanistic studies indicated that the effect of OOS was due to the induction of cell cycle arrest rather than the stimulation of apoptotic cell death. The cell cycle was slowed down in all phases in the HCC cell lines treated with OOS. Finally, when tested in animal models of HCC, OOS reduced tumor progression through the induction of necrosis in xenograft tumor models. Considering the poor prognosis and high resistance to antitumor treatments of HCC, the antiproliferative action of OOS, particularly in combination with sorafenib, provides the opportunity to investigate the effect of combined therapy in a clinical setting.